Dihexa

Dihexa (also known as PNB-0408 or N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide-derived compound developed at Washington State University through research into angiotensin metabolism. It emerged from investigations into the cognitive effects of hepatocyte growth factor (HGF) and its receptor c-Met — a signaling pathway important in neural development and repair. Dihexa was designed to be a potent agonist of the HGF/c-Met system, and its discovery revealed an unexpected potency: in animal models, Dihexa was found to be approximately 10 million times more potent than BDNF in promoting synaptogenesis (the formation of new neural synapses), making it by far the most potent known synaptogenic compound.

The distinction between synaptogenesis and neurogenesis is important for understanding Dihexa's significance. Neurogenesis (the creation of new neurons) has received considerable attention, but synaptic plasticity — the formation, strengthening, and reorganization of connections between existing neurons — is arguably more directly relevant to cognitive function in adults. The density and strength of synaptic connections correlates closely with learning capacity, working memory, and cognitive flexibility. Dihexa's HGF/c-Met mechanism drives the growth of dendritic spines and the formation of functional synaptic connections at concentrations orders of magnitude below those required by other known synaptogenic agents.

Published research from Washington State University demonstrated that Dihexa reversal of cognitive deficits in aged and scopolamine-impaired rats was dramatic and sustained — with effects persisting long after the compound was cleared from the system, consistent with a mechanism that builds new structural connections rather than simply modulating neurotransmitter activity. The researchers described the effect as one of the most robust cognitive enhancements observed in animal models, sufficient to restore aged animals to young-adult cognitive performance levels.

The critical limitation of Dihexa is the near-complete absence of published human safety and efficacy data. The animal research, while compelling, represents only preclinical evidence. The high potency that makes Dihexa interesting from a research perspective also raises legitimate questions about the consequences of off-target HGF/c-Met activation — HGF signaling plays roles in cellular proliferation, which in the context of cancer cells could theoretically be problematic. These concerns are theoretical rather than evidence-based, but they underscore why Dihexa remains in very early stages of human application and requires a genuinely conservative approach.